An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
Phase 2
Completed
- Conditions
- Warts
- Registration Number
- NCT00116662
- Lead Sponsor
- Graceway Pharmaceuticals, LLC
- Brief Summary
The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks.
A second purpose is to evaluate the safety of the drug.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 84
Inclusion Criteria
- Diagnosis of common wart(s)
- Ages between 3 to 11
Exclusion Criteria
- Other types of wart(s), ie. plantar
- Currently participating in another clinical study
- Chronic viral hepatitis B or C
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Clearance of treated common wart(s)
- Secondary Outcome Measures
Name Time Method Partial clearance of treated common wart(s) Wart recurrence
Trial Locations
- Locations (9)
Vermont
🇺🇸Burlington, Vermont, United States
Utah
🇺🇸Layton, Utah, United States
Massachusetts
🇺🇸Boston, Massachusetts, United States
Georgia
🇺🇸Newnan, Georgia, United States
Indiana
🇺🇸Lafayette, Indiana, United States
Missouri
🇺🇸St. Louis, Missouri, United States
Kansas
🇺🇸Wichita, Kansas, United States
Arkansas
🇺🇸Little Rock, Arkansas, United States
Illinois
🇺🇸Buffalo Grove, Illinois, United States